Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Boehringer Expands Graffinity Drug Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Boehringer Expands Graffinity Drug Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Boehringer Ingelheim Pharmaceuticals, Inc. has chosen to exercise options in its original agreement with Graffinity Pharmaceuticals that will increase the number of targets screened by Graffinity as part of this global alliance. Under the terms of the agreement, Graffinity will receive additional technology access fees for the generation of multiple small molecule hit series against a variety of drug targets from different therapeutic areas.

Graffinity will apply its fragment based drug discovery technology and drug fragment chemical microarrays to identify small molecule hit structures focusing on compounds with novel modes of action. Financial details were not disclosed.

Kristina Schmidt, chief executive officer of Graffinity, remarked, “Boehringer Ingelheim is taking full advantage of our proprietary process for rapidly identifying quality fragment hits. We believe that this collaboration is a validation of Graffinity’s approach of accelerating drug discovery through innovations in fragment based drug discovery.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics